Converting Cold into Hot Tumors by Combining Immunotherapies.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 28886376.
- Also identified by DOI 10.1016/j.cell.2017.08.031.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a small phase Ib study in this issue of Cell, Ribas et al. report that the combination of intralesional injection of a modified human herpes simplex virus and systemic anti-PD-1 treatment resulted in a 62% response rate in patients with metastatic melanoma, accompanied by enhanced T cell infiltration in virus-injected lesions.
Medical subject headings
- Immunotherapy
- Melanoma